Detalles de la búsqueda
1.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 24(12): 1359-1374, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37926100
2.
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Breast Cancer Res Treat
; 199(1): 35-46, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36859649
3.
The antigenic link between thyroid autoimmunity and breast cancer.
Semin Cancer Biol
; 64: 122-134, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31128301
4.
Modified Needleman-Wunsch algorithm for clinical pathway clustering.
J Biomed Inform
; 115: 103668, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33359110
5.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 18(7): 929-945, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28600210
6.
3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.
BMC Cancer
; 16: 345, 2016 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27251376
7.
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Lancet Oncol
; 15(1): 114-22, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24332514
8.
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Lancet Oncol
; 15(9): 997-1006, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25035292
9.
Breast-cancer adjuvant therapy with zoledronic acid.
N Engl J Med
; 365(15): 1396-405, 2011 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-21995387
10.
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
Lancet Oncol
; 14(10): 962-70, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23965225
11.
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Lancet Oncol
; 14(11): 1086-1094, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24055415
12.
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Lancet Oncol
; 14(12): 1216-25, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24095299
13.
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.
Breast Cancer Res Treat
; 138(3): 773-81, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23535839
14.
Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer.
Support Care Cancer
; 21(1): 173-81, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22644262
15.
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.
Breast Cancer Res
; 14(2): R46, 2012 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22417870
16.
Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
BMC Cancer
; 12: 458, 2012 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23039365
17.
Pro-metastatic tumor-stroma interactions in breast cancer.
Future Oncol
; 8(11): 1427-42, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23148616
18.
Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.
Breast Cancer Res Treat
; 125(3): 659-69, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20354780
19.
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Lancet
; 373(9676): 1681-92, 2009 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-19447249
20.
Effect of patient age on management decisions in breast cancer: consensus from a national consultation.
Oncologist
; 15(7): 657-64, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20551430